Real-world effectiveness of fecal microbiota transplantation for first or second Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.cgh.2024.05.038
Economic and Chronologic Optimization of Fecal Donors Screening Process.|https://dx.doi.org/10.1177/23814683241254809
Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy.|https://dx.doi.org/10.1002/imt2.200
Cyclic diguanylate differentially regulates the expression of virulence factors and pathogenesis-related phenotypes in Clostridioides difficile.|https://dx.doi.org/10.1016/j.micres.2024.127811
Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence.|https://dx.doi.org/10.3390/microorganisms12061206
Integrated Safety and Efficacy Analyses of PhaseÂ 3 Trials of a Microbiome Therapeutic for Recurrent CDI.|https://dx.doi.org/10.1007/s40121-024-01007-z
Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile.|https://dx.doi.org/10.1128/msphere.00273-24
Insoluble polysaccharides produced in plant cell cultures protect from Clostridioides difficile colitis.|https://dx.doi.org/10.1016/j.micres.2024.127812
Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.|https://dx.doi.org/10.1128/aac.00698-24
Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments.|https://dx.doi.org/10.1186/s40168-024-01820-1
Emerging importance of stool preservation methods in OMICS studies with special focus on cancer biology.|https://dx.doi.org/10.1002/cbf.4063
Occurrence and trends of Clostridioides difficile infections in hospitalized patients: a prospective multicentre cohort study in six German university hospitals, 2016-2020.|https://dx.doi.org/10.1016/j.jhin.2024.06.007
